Recombinant Human MICB His-tag Protein, CF

When Recombinant Human NKG2D/CD314 Fc Chimera (Catalog # 1299-NK) is immobilized at 0.125 μg/mL, 100 μL/mL, the concentration of Recombinant Human MICB His-tag (Catalog # 10431-MB) produces 50% of the optimal binding response is approximately 80‑400 ng/mL.

2 μg/lane of Recombinant Human MICB His-tag Protein (Catalog # 10431-MB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands 35-55 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human MICB His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human NKG2D/CD314 Fc Chimera (Catalog # 1299-NK) is immobilized at 0.125 μg/mL, 100 μL/well, the concentration of Recombinant Human MICB His-tag (Catalog # 10431-MB) that produces 50% of the optimal binding response is approximately 80-400 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human MICB protein
  Ala23-Thr308, with a C-terminal 6-His tag
• Accession #: NP_005922.2
• N-terminal Sequence: Ala23 & Glu24
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 33 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 35-55 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human MICB His-tag Protein, CF

• MHC class I chain-related protein B
• MHC class I mic-B antigen
• MHC class I polypeptide-related sequence B
• MICB
• MIC-B
• PERB11.2MHC class I-like molecule PERB11.2-IMX
• stress inducible class I homolog

Background

Major Histocompatibility Complex Class I Chain-related Gene B (MICB) is a transmembrane glycoprotein that functions as a ligand for human Natural-Killer Group 2 Member D (NKG2D) (1). MICB, along with the highly related MICA, are members of the non-classical MHC class I family. Similar to classical MHC class I proteins, MICB contains three Ig-like domains ( alpha 1, alpha 2, and alpha 3) in the extracellular domain (ECD), a transmembrane segment, and a carboxy-terminal cytoplasmic tail (2). The genes encoding MICA and MICB are found within the MHC on the short arm of human chromosome 6 and occur in most mammalian species but are absent from mouse and rat (2-4). Despite structural similarities, MICA/B only share ~27% amino acid (aa) identity with human MHC class I proteins (3). Both MICA and MICB display a significant degree of polymorphism within the ECD and this enables them to be reconfigured and bind with NKG2D rather than binding with beta 2-microglobulin (4, 5). Recognition of MICA/B by NKG2D results in the activation of cytolytic activity and/or cytokine production on NK cells, NKT cells, gamma δ T cells, and CD8+ alpha beta T cells (6, 7). MICA/B recognition is involved in tumor surveillance, viral infections, and autoimmune diseases. The release of soluble forms of MICA/B from tumors down-regulates NKG2D surface expression on effector cells resulting in the impairment of anti-tumor immune response (2, 8-11). Inhibition of MICA/B shedding through targeted antibodies allows anti-tumor immunity to be retained (12).

1. Huang, C. et al. (2018) Sci. Rep. 8:15821.
2. Bahram, S. et al. (1994) Proc. Natl. Acad. Sci. USA 91:6259.
3. Cosman, D. et al. (2001) Immunity 14:123.
4. Groh, V. et al. (2001) Nature Immunol. 2:255.
5. Stephens, H. (2001) Trends Immunol. 22:378.
6. Bauer, S. et al. (1999) Science 285:727.
7. Kawabata, Y. et al. (2000). Human Immunology. 61:624.
8. Groh, V. et al. (2002) Nature 419:734.
9. Steinle, A. et al. (2001) Immunogenetics 53:279.
10. Pende, D. et al. (2002) Cancer Res. 62:6178.
11. Salih, H. et al. (2003) Blood 102:1389.
12. Ferrari de Andrade et al. (2018) Science 359:1537.

Publications for MICB (10431-MB)(1)

Publication using 10431-MB

• Belevich, A;Yarmolinskaya, M;Smirnov, I;Stolbovaya, A;Shashkova, O;Samoylovich, M;Selkov, S;Grebenkina, P;Tyshchuk, E;Sokolov, D; sMICA/sMICB and Immune Checkpoint in Endometriosis: Toward a Minimally Invasive Diagnostic Model Based on Machine Learning Biomedicines 2026-03-12 [PMID: 41898293] (ELISA Standard, Human)

Bioinformatics

• Uniprot:
  • NP_005922.2()